^
Association details:
| Biomarker: | IDH2 mutation |
|---|---|
| Cancer: | Acute Myelogenous Leukemia |
| Drug: | Vyxeos (cytarabine/daunorubicin liposomal formulation) (DNA synthesis inhibitor, Topoisomerase II inhibitor, DNA polymerase inhibitor) |
| Direction: | Sensitive |
Evidence:
Source:
Title:
Genomic Landscape Impacts Induction Outcome with CPX-351 in Patients with Acute Myeloid Leukemia
Published date:
11/01/2018
Excerpt:
Although subgroup size is small, all patients (100%) with IDH1/2 or NPM1 mutations were responders to CPX-351 (n=12; p<0.001 for IDH1/2 and n=6; p=0.03 for NPM1).
DOI:
10.1182/blood-2018-99-117412
